Biovitrum Expands Kineret® License to Include Certain Orphan Indications
Stockholm, Sweden November 27, 2009 - Biovitrum AB (publ) (STO:BVT) today announced an agreement with Amgen to expand Biovitrum's Kineret license to include certain orphan indications. The amended license provides Biovitrum exclusive rights to develop, manufacture, market and sell Kineret for these additional orphan indications. In December 2008, Biovitrum obtained from Amgen the global exclusive rights to Kineret for rheumatoid arthritis as currently indicated on its label. "We are pleased that we now have the opportunity to further develop the innovative drug Kineret for rare serious diseases and make it available to additional patients with high unmet medical needs," said Martin Nicklasson, CEO of Biovitrum. Furthermore, we will be able to further leverage Kineret product value and the agreement validates our good and longstanding relationship with Amgen," Nicklasson added. About Kineret® (anakinra) Information about Kineret® can be found at the following site: http://www.kineretrx.com/ Healthcare professionals should refer to and rely upon the PDR (Physician's Desk Reference) or the corresponding national labeling texts. About Biovitrum Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit www.biovitrum.com. For further information, please contact Biovitrum AB (publ) Erik Kinnman, EVP Investor Relations Phone: +46 73 422 15 40 erik.kinnman@biovitrum.com Martin Nicklasson, CEO Phone. +46 8 697 2327 Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on November 27, 2009 at 8.30 a.m. CET.